Kura Oncology Q1 net loss $57.4M; NDA submitted for ziftomenib, $45M milestone earned

Kura Oncology, Inc.

2025-Q1 EPS reported -$0.66 revenue$14,108,000

NDA for ziftomenib in R/R NPM1-mutant AML submitted March 31, 2025; FDA review period expected Q2 2025.
Earned $45 million milestone from Kyowa Kirin for NDA submission; pro forma cash $703.2M.
Q1 collaboration revenue $14.1M (vs $0 in Q1 2024); R&D expenses $56.0M, up 54% YoY.
Cash, equivalents and short-term investments $658.2M at March 31, 2025; runway into 2027.
First patients dosed in Phase 1 trial of ziftomenib plus imatinib in GIST; data at ASCO and EHA upcoming.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.